Patents Examined by Shri Ponnaluri
-
Patent number: RE45847Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies.Type: GrantFiled: March 19, 2014Date of Patent: January 19, 2016Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Nicholas Pullen, Elizabeth Molloy, Sirid-Aimee Kellermann, Larry L. Green, Mary Haak-Frendscho
-
Patent number: RE45992Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: July 23, 2014Date of Patent: May 3, 2016Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Patent number: RE46042Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: GrantFiled: May 16, 2013Date of Patent: June 28, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
-
Patent number: RE46117Abstract: New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1), wherein X N, CH, or C, however X may only be C when the compound comprises a double bond at the dotted line; R1 is OSO2CF3, OSO2CH3, SOR3, SO2R3, COR3, NO2, or CONHR3 and when X is CH or C R1 may also be CF3, CN, F, Cl, Br, or I; R2 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4,-trifluorobutyl, or —(CH2)—R4; R3 is a C1-C3 alkyl CF3, or N(R2)2; R4 is a C3-C6 cycloalkyl, 2-tetrahydrofurane or 3-tetra-hydrofurane, as well as pharmaceutically acceptable salts thereof are disclosed.Type: GrantFiled: April 22, 2015Date of Patent: August 23, 2016Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBHInventors: Clas Sonesson, Bengt Andersson, Susanna Waters, Nicholas Waters, Joakim Tedroff
-
Patent number: RE46373Abstract: Diagnosing or treating a human ear includes transporting a conjugated nanoparticle or a magnetically responsive nanoparticle into a human's middle or inner ear. Otologic nanophoresis includes electrically, magnetically or electromagnetically driving a nanoparticle through a membrane of the ear, including a tympanic membrane, a round window membrane, an oval window membrane, or a circulatory membrane. An otologic diagnostic device includes a nanoparticle conjugated with a material selected from the group consisting of lipids, proteins, growth factors, growth hormones, antioxidants, free radical scavengers, steroid preparations, and metabolically active substances; an otologic therapeutic device includes the same categories of substances and chemotherapeutic drugs. Another otologic composition includes a nanoparticle conjugated with a substance perceptible to magnetic resonance imaging.Type: GrantFiled: November 5, 2014Date of Patent: April 25, 2017Assignee: HOUGH EAR INSTITUTEInventors: R. Kent Dyer, Jr., Jack V. D. Hough
-
Patent number: RE46379Abstract: The present invention relates to a method of determining the presence of a retinoblastoma protein (Rb)-mediated cancerous or pre-cancerous condition in a sample of fixed cells that involves exposing the sample to an antibody that recognizes phosphorylation of serine on the retinoblastoma protein (pS-Rb), and identifying cells in the sample that are recognized by the antibody to pS-Rb, where the recognition of pS-Rb in the sample determines the presence of an Rb-mediated cancerous or pre-cancerous condition. The method also involves identifying the presence of specific cell cycle markers and positive and negative cell cycle regulators to assess the stage of disease progression in a cancer patient having an (Rb)-mediated cancer. The present invention also relates to methods of assessing the efficacy of cancer therapy for an Rb-mediated cancer, determining the mechanism of cell cycle progression in an Rb-mediated cancer, and identifying cells predisposed to developing an Rb-mediated cancerous condition.Type: GrantFiled: December 9, 2015Date of Patent: April 25, 2017Assignee: Cornell Research Foundation, Inc.Inventors: Selina Chen-Kiang, Scott A. Ely, Maurizio DiLiberto
-
Patent number: RE46382Abstract: Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.Type: GrantFiled: October 2, 2015Date of Patent: May 2, 2017Assignee: SanBio, Inc.Inventors: Mo Dao, Casey C. Case
-
Patent number: RE46425Abstract: This present invention is directed to peptides, compositions, and methods for modulating endogenous cytokine expression in a subject. More specifically, the invention provides peptides useful in regulating the release of a specific pattern of cytokines that promote angiogenesis and/or can be used to modulate the immune system of a subject.Type: GrantFiled: June 9, 2015Date of Patent: June 6, 2017Assignee: Susavion Biosciences, Inc.Inventors: Laura L. Eggink, J. Kenneth Hoober
-
Patent number: RE46534Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.Type: GrantFiled: April 29, 2015Date of Patent: September 5, 2017Assignee: Genentech, Inc.Inventors: Daryl T. Baldwin, Sarah C. Bodary-Winter, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
-
Patent number: RE46583Abstract: Vaccination with the combination of Ag85B-TB10.4 and IC31® adjuvant generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-?, TNF-?, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Both the immunogenicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5 ?g, as well as 15 ?g, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 ?g increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the IC31® adjuvant, with the specified antigen dose, can induce a strong protective Th1 response against M. tuberculosis.Type: GrantFiled: September 11, 2015Date of Patent: October 24, 2017Assignee: Statens Serum InstitutInventors: Jes Dietrich, Claus Aagaard, Peter Andersen
-
Patent number: RE46585Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: January 12, 2016Date of Patent: October 24, 2017Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Patent number: RE46631Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: May 17, 2013Date of Patent: December 12, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai
-
Patent number: RE46641Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: May 17, 2013Date of Patent: December 19, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai
-
Patent number: RE46805Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.Type: GrantFiled: March 27, 2014Date of Patent: April 24, 2018Assignee: Genentech, Inc.Inventors: Daryl T. Baldwin, Sarah C. Bodary-Winter, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
-
Patent number: RE46816Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases involving detection of the PRO52254 polypeptide.Type: GrantFiled: March 27, 2014Date of Patent: May 1, 2018Assignee: Genentech, Inc.Inventors: Daryl T. Baldwin, Sarah C. Bodary-Winter, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
-
Patent number: RE46873Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.Type: GrantFiled: May 26, 2016Date of Patent: May 29, 2018Assignee: Sirnaomics, Inc.Inventors: Patrick Y. Lu, Ling Li, Vera Simonenko
-
Patent number: RE46877Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: November 21, 2012Date of Patent: May 29, 2018Assignee: BTG INTERNATIONAL LIMITEDInventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
-
Patent number: RE47150Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: GrantFiled: July 12, 2016Date of Patent: December 4, 2018Assignee: Bayer HealthCare LLCInventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska-Goebel, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brückner, Susanne Steinig, Peter Scholz
-
Patent number: RE47761Abstract: The invention provides anti-Axl antibodies and methods of using the same.Type: GrantFiled: October 6, 2016Date of Patent: December 10, 2019Assignee: Genentech, Inc.Inventors: Lin Pei, Yan Wu, Xiaofen Ye